In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

B. Braun: Everywhere But Here

Executive Summary

Founded over 160 years ago, Germany-based B. Braun is a leading hospital supplier of medical supplies and products around the globe, combining a broad product and a strong service component. Pursuing a broad-based strategy that seeks to leverage its wide array of products, a la American Hospital Supply Corp., B. Braun officials nonetheless understand the importance of having state-of-the-art products in its many technology categories. Its US business has been less successful, raising the question why strong foreign suppliers often find it difficult to crack the US marketplace. But B. Braun is anything but a cautious, conservative, family-owned company, as its long history might suggest. From manufacturing to corporate culture, the company relentlessly pursues the latest and most up-to-date approaches.

You may also be interested in...



B. Braun's Bet on Balloons

Until now, B. Braun, one of the oldest players in cardiovascular devices, has been comfortable in its niche. B. Braun's cardiovascular business is actually made up of two units, one that makes products for interventional radiologists and surgeons in the peripheral field, the other on a range of devices used in interventional cardiology. But the investment the company is making in a new technology, drug-eluting balloons, could be disruptive, if not to interventional cardiology, at least to the cardiovascular device companies and none more so than B. Braun itself.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel